Evaluation of the intranasal route for porcine reproductive and respiratory disease modified-live virus vaccination
•Porcine reproductive and respiratory syndrome virus is important in pigs.•The virus commonly infects pigs via the respiratory system.•Vaccination is commonly administered via the intramuscular route.•A prototype nasal jet device that could be used for mass vaccination was investigated.•Intramuscula...
Gespeichert in:
Veröffentlicht in: | Vaccine 2021-11, Vol.39 (47), p.6852-6859 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 6859 |
---|---|
container_issue | 47 |
container_start_page | 6852 |
container_title | Vaccine |
container_volume | 39 |
creator | Opriessnig, Tanja Rawal, Gaurav McKeen, Lauren Filippsen Favaro, Patricia Halbur, Patrick G. Gauger, Phillip C. |
description | •Porcine reproductive and respiratory syndrome virus is important in pigs.•The virus commonly infects pigs via the respiratory system.•Vaccination is commonly administered via the intramuscular route.•A prototype nasal jet device that could be used for mass vaccination was investigated.•Intramuscular and intranasal vaccine efficacy was comparable in a pig challenge.•Pigs vaccinated intranasally had higher neutralizing antibody levels at challenge.
In pigs, modified live virus (MLV) vaccines against porcine reproductive and respiratory syndrome virus (PRRSV) are commonly used and administered by intramuscular (IM) injection. In contrast, PRRSV, as a primary respiratory pathogen, is mainly transmitted via the intranasal (IN) route. The objective of this study was to evaluate the efficacy of a commonly used commercial PRRSV MLV delivered IN compared to the IM route.
Fifty-four pigs were divided into five treatment groups. All vaccinated groups received the same MLV vaccine but administered via different routes. Group IN-JET-VAC was vaccinated with an automated high pressure prototype nasal jet device (IN-JET-VAC, n = 12), group IN-MAD-VAC was vaccinated with a mucosal atomization device (IN-MAD-VAC, n = 12), group IM-VAC was vaccinated intramuscularly (IM-VAC; n = 12) according to label instructions, while the NEG-CONTROL (n = 6) and the POS-CONTROL (n = 12) groups were both unvaccinated. At 28 days post vaccination all vaccinated groups and the POS-CONTROL pigs were challenged with a pathogenic US PRRSV isolate. Blood and nasal swabs were collected at regular intervals, and all pigs were necropsied at day 10 post challenge (dpc) when gross and microscopic lung lesions were assessed.
Prior to challenge most vaccinated pigs had seroconverted to PRRSV. Clinical signs (fever, inappetence) were most obvious in the POS-CONTROL group from dpc 7 onwards. The vaccinated groups were not different for PRRSV viremia, seroconversion, or average daily weight gain. However, IN-JET-VAC and IN-MAD-VAC had significantly higher neutralizing antibody levels against the vaccine virus at challenge.
Comparable vaccine responses were obtained in IN and IM vaccinated pigs, suggesting the intranasal administration route as an alternative option for PRRSV vaccination. |
doi_str_mv | 10.1016/j.vaccine.2021.10.033 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2587765489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X21013530</els_id><sourcerecordid>2587765489</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-34368a2d85cf091957ee578d87144113b6e52fc67ed516544ced58aaf28eb7dd3</originalsourceid><addsrcrecordid>eNqFkcFrHCEYxSU0JJs0f0KK0Esvs9FRR-dUyrJJC4FeEuhNXP2GuMyOW3UG8t_XyWx66KUn5fF73_f0IXRLyZoS2tzt15Ox1g-wrklNi7YmjJ2hFVWSVbWg6gNakbrhFafk1yW6SmlPCBGMthfoknFJGsXJCqXtZPrRZB8GHDqcXwD7IUczmGR6HMOYAXch4mOI8zIc4RiDG232E2AzuCKko48mh_iKnU9gEuBDcL7z4Kp-piYfx4SXtG-LPqLzzvQJbk7nNXq-3z5tvlePPx9-bL49VpZzkivGWaNM7ZSwHWlpKySAkMopSTmnlO0aEHVnGwlO0EZwbstFGdPVCnbSOXaNvixzS-TfI6SsDz5Z6HszQBiTroWSshhVW9DP_6D7MMahpCtU23CuBJGFEgtlY0gpQqeP0R9MfNWU6LkVvdenVvTcyiyXVorv02n6uDuA--t6r6EAXxcAyndMHqJO1sNQHuQj2Kxd8P9Z8QdsqaJZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2596448507</pqid></control><display><type>article</type><title>Evaluation of the intranasal route for porcine reproductive and respiratory disease modified-live virus vaccination</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Opriessnig, Tanja ; Rawal, Gaurav ; McKeen, Lauren ; Filippsen Favaro, Patricia ; Halbur, Patrick G. ; Gauger, Phillip C.</creator><creatorcontrib>Opriessnig, Tanja ; Rawal, Gaurav ; McKeen, Lauren ; Filippsen Favaro, Patricia ; Halbur, Patrick G. ; Gauger, Phillip C.</creatorcontrib><description>•Porcine reproductive and respiratory syndrome virus is important in pigs.•The virus commonly infects pigs via the respiratory system.•Vaccination is commonly administered via the intramuscular route.•A prototype nasal jet device that could be used for mass vaccination was investigated.•Intramuscular and intranasal vaccine efficacy was comparable in a pig challenge.•Pigs vaccinated intranasally had higher neutralizing antibody levels at challenge.
In pigs, modified live virus (MLV) vaccines against porcine reproductive and respiratory syndrome virus (PRRSV) are commonly used and administered by intramuscular (IM) injection. In contrast, PRRSV, as a primary respiratory pathogen, is mainly transmitted via the intranasal (IN) route. The objective of this study was to evaluate the efficacy of a commonly used commercial PRRSV MLV delivered IN compared to the IM route.
Fifty-four pigs were divided into five treatment groups. All vaccinated groups received the same MLV vaccine but administered via different routes. Group IN-JET-VAC was vaccinated with an automated high pressure prototype nasal jet device (IN-JET-VAC, n = 12), group IN-MAD-VAC was vaccinated with a mucosal atomization device (IN-MAD-VAC, n = 12), group IM-VAC was vaccinated intramuscularly (IM-VAC; n = 12) according to label instructions, while the NEG-CONTROL (n = 6) and the POS-CONTROL (n = 12) groups were both unvaccinated. At 28 days post vaccination all vaccinated groups and the POS-CONTROL pigs were challenged with a pathogenic US PRRSV isolate. Blood and nasal swabs were collected at regular intervals, and all pigs were necropsied at day 10 post challenge (dpc) when gross and microscopic lung lesions were assessed.
Prior to challenge most vaccinated pigs had seroconverted to PRRSV. Clinical signs (fever, inappetence) were most obvious in the POS-CONTROL group from dpc 7 onwards. The vaccinated groups were not different for PRRSV viremia, seroconversion, or average daily weight gain. However, IN-JET-VAC and IN-MAD-VAC had significantly higher neutralizing antibody levels against the vaccine virus at challenge.
Comparable vaccine responses were obtained in IN and IM vaccinated pigs, suggesting the intranasal administration route as an alternative option for PRRSV vaccination.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2021.10.033</identifier><identifier>PMID: 34706840</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Administration, Intranasal ; Animal diseases ; Animals ; Antibodies ; Antibodies, Viral ; Appetite loss ; Atomizing ; Evaluation ; Fever ; High pressure ; Hogs ; Intranasal administration ; Lungs ; Lymphatic system ; Mucosa ; Porcine Reproductive and Respiratory Syndrome - prevention & control ; Porcine respiratory and reproductive syndrome virus ; Respiratory diseases ; Seroconversion ; Swine ; Vaccination ; Vaccines ; Vaccines, Attenuated ; Viral diseases ; Viral Vaccines ; Viremia ; Virulence ; Viruses</subject><ispartof>Vaccine, 2021-11, Vol.39 (47), p.6852-6859</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-34368a2d85cf091957ee578d87144113b6e52fc67ed516544ced58aaf28eb7dd3</citedby><cites>FETCH-LOGICAL-c440t-34368a2d85cf091957ee578d87144113b6e52fc67ed516544ced58aaf28eb7dd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2596448507?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34706840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Opriessnig, Tanja</creatorcontrib><creatorcontrib>Rawal, Gaurav</creatorcontrib><creatorcontrib>McKeen, Lauren</creatorcontrib><creatorcontrib>Filippsen Favaro, Patricia</creatorcontrib><creatorcontrib>Halbur, Patrick G.</creatorcontrib><creatorcontrib>Gauger, Phillip C.</creatorcontrib><title>Evaluation of the intranasal route for porcine reproductive and respiratory disease modified-live virus vaccination</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•Porcine reproductive and respiratory syndrome virus is important in pigs.•The virus commonly infects pigs via the respiratory system.•Vaccination is commonly administered via the intramuscular route.•A prototype nasal jet device that could be used for mass vaccination was investigated.•Intramuscular and intranasal vaccine efficacy was comparable in a pig challenge.•Pigs vaccinated intranasally had higher neutralizing antibody levels at challenge.
In pigs, modified live virus (MLV) vaccines against porcine reproductive and respiratory syndrome virus (PRRSV) are commonly used and administered by intramuscular (IM) injection. In contrast, PRRSV, as a primary respiratory pathogen, is mainly transmitted via the intranasal (IN) route. The objective of this study was to evaluate the efficacy of a commonly used commercial PRRSV MLV delivered IN compared to the IM route.
Fifty-four pigs were divided into five treatment groups. All vaccinated groups received the same MLV vaccine but administered via different routes. Group IN-JET-VAC was vaccinated with an automated high pressure prototype nasal jet device (IN-JET-VAC, n = 12), group IN-MAD-VAC was vaccinated with a mucosal atomization device (IN-MAD-VAC, n = 12), group IM-VAC was vaccinated intramuscularly (IM-VAC; n = 12) according to label instructions, while the NEG-CONTROL (n = 6) and the POS-CONTROL (n = 12) groups were both unvaccinated. At 28 days post vaccination all vaccinated groups and the POS-CONTROL pigs were challenged with a pathogenic US PRRSV isolate. Blood and nasal swabs were collected at regular intervals, and all pigs were necropsied at day 10 post challenge (dpc) when gross and microscopic lung lesions were assessed.
Prior to challenge most vaccinated pigs had seroconverted to PRRSV. Clinical signs (fever, inappetence) were most obvious in the POS-CONTROL group from dpc 7 onwards. The vaccinated groups were not different for PRRSV viremia, seroconversion, or average daily weight gain. However, IN-JET-VAC and IN-MAD-VAC had significantly higher neutralizing antibody levels against the vaccine virus at challenge.
Comparable vaccine responses were obtained in IN and IM vaccinated pigs, suggesting the intranasal administration route as an alternative option for PRRSV vaccination.</description><subject>Administration, Intranasal</subject><subject>Animal diseases</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Viral</subject><subject>Appetite loss</subject><subject>Atomizing</subject><subject>Evaluation</subject><subject>Fever</subject><subject>High pressure</subject><subject>Hogs</subject><subject>Intranasal administration</subject><subject>Lungs</subject><subject>Lymphatic system</subject><subject>Mucosa</subject><subject>Porcine Reproductive and Respiratory Syndrome - prevention & control</subject><subject>Porcine respiratory and reproductive syndrome virus</subject><subject>Respiratory diseases</subject><subject>Seroconversion</subject><subject>Swine</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Attenuated</subject><subject>Viral diseases</subject><subject>Viral Vaccines</subject><subject>Viremia</subject><subject>Virulence</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcFrHCEYxSU0JJs0f0KK0Esvs9FRR-dUyrJJC4FeEuhNXP2GuMyOW3UG8t_XyWx66KUn5fF73_f0IXRLyZoS2tzt15Ox1g-wrklNi7YmjJ2hFVWSVbWg6gNakbrhFafk1yW6SmlPCBGMthfoknFJGsXJCqXtZPrRZB8GHDqcXwD7IUczmGR6HMOYAXch4mOI8zIc4RiDG232E2AzuCKko48mh_iKnU9gEuBDcL7z4Kp-piYfx4SXtG-LPqLzzvQJbk7nNXq-3z5tvlePPx9-bL49VpZzkivGWaNM7ZSwHWlpKySAkMopSTmnlO0aEHVnGwlO0EZwbstFGdPVCnbSOXaNvixzS-TfI6SsDz5Z6HszQBiTroWSshhVW9DP_6D7MMahpCtU23CuBJGFEgtlY0gpQqeP0R9MfNWU6LkVvdenVvTcyiyXVorv02n6uDuA--t6r6EAXxcAyndMHqJO1sNQHuQj2Kxd8P9Z8QdsqaJZ</recordid><startdate>20211116</startdate><enddate>20211116</enddate><creator>Opriessnig, Tanja</creator><creator>Rawal, Gaurav</creator><creator>McKeen, Lauren</creator><creator>Filippsen Favaro, Patricia</creator><creator>Halbur, Patrick G.</creator><creator>Gauger, Phillip C.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20211116</creationdate><title>Evaluation of the intranasal route for porcine reproductive and respiratory disease modified-live virus vaccination</title><author>Opriessnig, Tanja ; Rawal, Gaurav ; McKeen, Lauren ; Filippsen Favaro, Patricia ; Halbur, Patrick G. ; Gauger, Phillip C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-34368a2d85cf091957ee578d87144113b6e52fc67ed516544ced58aaf28eb7dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Intranasal</topic><topic>Animal diseases</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Viral</topic><topic>Appetite loss</topic><topic>Atomizing</topic><topic>Evaluation</topic><topic>Fever</topic><topic>High pressure</topic><topic>Hogs</topic><topic>Intranasal administration</topic><topic>Lungs</topic><topic>Lymphatic system</topic><topic>Mucosa</topic><topic>Porcine Reproductive and Respiratory Syndrome - prevention & control</topic><topic>Porcine respiratory and reproductive syndrome virus</topic><topic>Respiratory diseases</topic><topic>Seroconversion</topic><topic>Swine</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Attenuated</topic><topic>Viral diseases</topic><topic>Viral Vaccines</topic><topic>Viremia</topic><topic>Virulence</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Opriessnig, Tanja</creatorcontrib><creatorcontrib>Rawal, Gaurav</creatorcontrib><creatorcontrib>McKeen, Lauren</creatorcontrib><creatorcontrib>Filippsen Favaro, Patricia</creatorcontrib><creatorcontrib>Halbur, Patrick G.</creatorcontrib><creatorcontrib>Gauger, Phillip C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Opriessnig, Tanja</au><au>Rawal, Gaurav</au><au>McKeen, Lauren</au><au>Filippsen Favaro, Patricia</au><au>Halbur, Patrick G.</au><au>Gauger, Phillip C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the intranasal route for porcine reproductive and respiratory disease modified-live virus vaccination</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2021-11-16</date><risdate>2021</risdate><volume>39</volume><issue>47</issue><spage>6852</spage><epage>6859</epage><pages>6852-6859</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•Porcine reproductive and respiratory syndrome virus is important in pigs.•The virus commonly infects pigs via the respiratory system.•Vaccination is commonly administered via the intramuscular route.•A prototype nasal jet device that could be used for mass vaccination was investigated.•Intramuscular and intranasal vaccine efficacy was comparable in a pig challenge.•Pigs vaccinated intranasally had higher neutralizing antibody levels at challenge.
In pigs, modified live virus (MLV) vaccines against porcine reproductive and respiratory syndrome virus (PRRSV) are commonly used and administered by intramuscular (IM) injection. In contrast, PRRSV, as a primary respiratory pathogen, is mainly transmitted via the intranasal (IN) route. The objective of this study was to evaluate the efficacy of a commonly used commercial PRRSV MLV delivered IN compared to the IM route.
Fifty-four pigs were divided into five treatment groups. All vaccinated groups received the same MLV vaccine but administered via different routes. Group IN-JET-VAC was vaccinated with an automated high pressure prototype nasal jet device (IN-JET-VAC, n = 12), group IN-MAD-VAC was vaccinated with a mucosal atomization device (IN-MAD-VAC, n = 12), group IM-VAC was vaccinated intramuscularly (IM-VAC; n = 12) according to label instructions, while the NEG-CONTROL (n = 6) and the POS-CONTROL (n = 12) groups were both unvaccinated. At 28 days post vaccination all vaccinated groups and the POS-CONTROL pigs were challenged with a pathogenic US PRRSV isolate. Blood and nasal swabs were collected at regular intervals, and all pigs were necropsied at day 10 post challenge (dpc) when gross and microscopic lung lesions were assessed.
Prior to challenge most vaccinated pigs had seroconverted to PRRSV. Clinical signs (fever, inappetence) were most obvious in the POS-CONTROL group from dpc 7 onwards. The vaccinated groups were not different for PRRSV viremia, seroconversion, or average daily weight gain. However, IN-JET-VAC and IN-MAD-VAC had significantly higher neutralizing antibody levels against the vaccine virus at challenge.
Comparable vaccine responses were obtained in IN and IM vaccinated pigs, suggesting the intranasal administration route as an alternative option for PRRSV vaccination.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>34706840</pmid><doi>10.1016/j.vaccine.2021.10.033</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2021-11, Vol.39 (47), p.6852-6859 |
issn | 0264-410X 1873-2518 |
language | eng |
recordid | cdi_proquest_miscellaneous_2587765489 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
subjects | Administration, Intranasal Animal diseases Animals Antibodies Antibodies, Viral Appetite loss Atomizing Evaluation Fever High pressure Hogs Intranasal administration Lungs Lymphatic system Mucosa Porcine Reproductive and Respiratory Syndrome - prevention & control Porcine respiratory and reproductive syndrome virus Respiratory diseases Seroconversion Swine Vaccination Vaccines Vaccines, Attenuated Viral diseases Viral Vaccines Viremia Virulence Viruses |
title | Evaluation of the intranasal route for porcine reproductive and respiratory disease modified-live virus vaccination |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T05%3A13%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20intranasal%20route%20for%20porcine%20reproductive%20and%20respiratory%20disease%20modified-live%20virus%20vaccination&rft.jtitle=Vaccine&rft.au=Opriessnig,%20Tanja&rft.date=2021-11-16&rft.volume=39&rft.issue=47&rft.spage=6852&rft.epage=6859&rft.pages=6852-6859&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2021.10.033&rft_dat=%3Cproquest_cross%3E2587765489%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2596448507&rft_id=info:pmid/34706840&rft_els_id=S0264410X21013530&rfr_iscdi=true |